8-K: Corbus Pharmaceuticals Terminates At-the-Market Offering Prospectus Supplement

Corbus Pharmaceuticals has terminated its at-the-market offering prospectus supplement, halting immediate sales of common stock, but the underlying sales agreement remains active.

Summary

• Corbus Pharmaceuticals has terminated its prospectus supplement related to its at-the-market (ATM) offering of common stock.
• The termination was effective January 30, 2024, following a written notice to Jefferies LLC.
• The company will not sell any securities under the ATM offering until a new prospectus supplement is filed.
• The original Open Market Sale Agreement with Jefferies LLC, dated August 6, 2020, remains in effect.

Sentiment

Score: 5

Explanation: The news is neutral, indicating a pause in a specific capital-raising activity, but the underlying agreement remains in place. It's not inherently positive or negative.

Positives

• The underlying Open Market Sale Agreement with Jefferies LLC remains active, providing future flexibility for capital raising.

Negatives

• The termination of the ATM prospectus supplement temporarily halts the company's ability to raise capital through this specific mechanism.

Risks

• The company may face challenges in raising capital if a new prospectus supplement is not filed promptly.
• The termination of the ATM offering could indicate a change in the company's financial strategy or market conditions.

Future Outlook

The company will not make any sales of its securities pursuant to the Sale Agreement, unless and until a new prospectus supplement is filed.

Management Comments

• The company delivered written notice to Jefferies LLC that it was suspending and terminating the prospectus supplement.

Industry Context

The termination of an ATM offering is not uncommon and can be due to various factors, including market conditions or a change in the company's financing strategy. It is important to monitor if and when a new prospectus supplement is filed.

Comparison to Industry Standards

• Many biotech companies utilize at-the-market offerings as a flexible way to raise capital.
• The termination of an ATM prospectus supplement is not unusual and can be a strategic decision based on market conditions or company needs.
• Companies like Xencor and BioMarin have used ATM offerings in the past, and their actions can be compared to Corbus's decision to terminate the prospectus supplement.

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the termination of the ATM offering.
• The company's ability to fund operations and research may be temporarily affected.

Next Steps

• The company will need to file a new prospectus supplement to resume sales of common stock under the ATM offering.

Key Dates

Keywords

at-the-market offering, ATM, prospectus supplement, common stock, capital raise, Jefferies LLC, securities, Corbus Pharmaceuticals